Rarity Bioscience’s Alexander Kele and Ann-Sofi Johansson attended the biannual ESH AML Conference, in Estoril (Portugal). They were there not only to discuss MRD testing but also to support the poster presentation “Utility of Blood vs Bone marrow for molecular MRD in AML and MDS”.
”We are grateful to Anna Robelius (Hematology specialist at Uppsala University Hospital) for such an interesting presentation of both her clinical work and the superRCA technology”
Ann-Sofi Johansson
Product Development Manager
Rarity Bioscience
”It’s been an interesting conference all through and I am grateful to the organizers for pulling together scientists across the board from basic research to cancer biology, in vivo and clinical studies.”
Alexander Kele
Product Development Manager, Rarity Bioscience
The poster is available for download: Utility of Blood vs Bone marrow for molecular MRD in AML and MDS – superRCA, an ultra-sensitive mutation detection method using flow cytometer readout.
